Research Analysts Offer Predictions for ACRS FY2027 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a note issued to investors on Monday, March 16th. HC Wainwright analyst R. Selvaraju forecasts that the biotechnology company will post earnings of ($0.55) per share for the year. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. Craig Hallum initiated coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 target price on the stock. Finally, Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Stock Performance

Shares of ACRS opened at $3.74 on Tuesday. The stock has a market capitalization of $451.04 million, a PE ratio of -7.06 and a beta of 0.88. Aclaris Therapeutics has a 1 year low of $1.05 and a 1 year high of $4.89. The company’s 50-day simple moving average is $3.33 and its 200-day simple moving average is $2.73.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million. Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%.

Hedge Funds Weigh In On Aclaris Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ProShare Advisors LLC purchased a new stake in shares of Aclaris Therapeutics during the second quarter worth approximately $26,000. AXQ Capital LP purchased a new position in Aclaris Therapeutics in the third quarter worth approximately $27,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Aclaris Therapeutics in the second quarter worth approximately $28,000. XTX Topco Ltd acquired a new position in Aclaris Therapeutics during the 2nd quarter worth approximately $34,000. Finally, R Squared Ltd acquired a new position in Aclaris Therapeutics during the 4th quarter worth approximately $37,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.